公开(公告)号：US20250100997A1

公开(公告)日：2025-03-27

申请号：US18728106

申请日：2023-01-10

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Daniela PIZZIRANI ,  Paolo RONCHI ,  Donatella RESCIGNO

IPC: C07D401/14 ,  A61K31/501 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.

公开(公告)号：US20250011299A1

公开(公告)日：2025-01-09

申请号：US18693564

申请日：2022-09-20

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Daniela PIZZIRANI ,  Paolo RONCHI ,  Sara GUARIENTO ,  Daniele PALA ,  Paolo BRUNO ,  Teresa SEMERARO ,  Donatella RESCIGNO

IPC: C07D401/12 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10 ,  C07D487/18 ,  C07D491/107

Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.

公开(公告)号：US20240116948A1

公开(公告)日：2024-04-11

申请号：US18269042

申请日：2021-12-20

Applicant: CHIESI FARMACEUTICI S.P.A.

Inventor： Daniele PALA ,  Daniela PIZZIRANI ,  Paolo BRUNO ,  Matteo BIAGETTI ,  Paolo RONCHI ,  Sara GUARIENTO ,  Barbara BERTANI ,  Donatella RESCIGNO

IPC: C07D498/04 ,  C07D519/00

CPC classification number: C07D498/04 ,  C07D519/00

Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.